Nektar Therapeutics logo
Nektar Therapeutics
NKTR | NASDAQ
Chart Builder DCF Calculator
$36.44
-$0.83 (-2.23%)
At close: Nov 16, 2026, 4:00 PM ET
$36.29
-$0.15 (-0.41%)
After-hours: Nov 16, 2026, 7:30 PM ET

Nektar Therapeutics Company Profile

Company profile explained

Company Profile

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Key Executives

Name Position
Howard W. Robin Chief Executive Officer, President & Director
Linda Rubinstein Chief Financial Officer and Principal Financial & Accounting Officer
Robert Bacci Chief People Officer and Head of Quality & Facilities
Elizabeth Zhang VP of Legal, Corporate Counsel & Secretary
Jason Barnard Chief Accounting Officer
Jennifer Ruddock Chief Business Officer
Jonathan Zalevsky Senior Vice President and Chief Research & Development Officer
Ken Franke Senior Vice President of Biologics Process Development & Manufacturing
Mary Tagliaferri Chief Medical Officer
Spilios Asimakopoulos Vice President of Commercial Strategy & Marketing

Latest SEC Filings

Date Type Title
Oct 20, 2026 S-8 Filing
Oct 01, 2026 8-K Current Report
Sep 28, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 4 Filing
Sep 25, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
View All SEC Filings ➞
Nektar Therapeutics
Nektar Therapeutics logo
Country United States
IPO Date May 3, 1994
Industry Biotechnology
Sector Healthcare
Employees 63
CEO Howard W. Robin

Contact Details

455 Mission Bay Boulevard South San Francisco, California 94158 United States

Stock Details

Ticker Symbol NKTR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000906709
CUSIP Number 640268306
ISIN Number US6402683063
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.